<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluorouracil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00544</strong>&#160; (APRD00516, EXPT03204)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with <span class="caps">DNA</span> synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00544/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00544/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00544.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00544.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00544.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00544.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00544.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00544">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-Fluorouracil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Fluracil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-FU</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fluoro Uracil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fluouracil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>FU</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adrucil</td><td>Adria</td></tr><tr><td>Carac</td><td>Sanofi</td></tr><tr><td>Carzonal</td><td>Tobishi</td></tr><tr><td>Efudex</td><td>Valeant</td></tr><tr><td>Efudix</td><td>Meda</td></tr><tr><td>Efurix</td><td>Valeant</td></tr><tr><td>Fluoroplex</td><td>Aqua</td></tr><tr><td>Ftoruracil</td><td>Verofarm</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/antimetabolites">Antimetabolites</a></li>
<li><a href="/mesh/antimetabolites-antineoplastic">Antimetabolites, Antineoplastic</a></li></ul></td></tr><tr><th>CAS number</th><td>51-21-8</td></tr><tr><th>Weight</th><td>Average: 130.0772<br>Monoisotopic: 130.017855555</td></tr><tr><th>Chemical Formula</th><td>C<sub>4</sub>H<sub>3</sub>FN<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>GHASVSINZRGABV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">FC1=CNC(=O)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00544.gif?1265922772">show</a>(7.93 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Halopyrimidines</td></tr><tr><th>Alternative parents</th><td>Pyrimidones; Hydropyrimidines; Aryl Fluorides; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>aryl fluoride; aryl halide; hydropyrimidine; polyamine; organofluoride; organohalogen; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the halopyrimidines. These are aromatic compounds containing an halogen atom linked to a pyrimidine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.</td></tr><tr><th>Pharmacodynamics</th><td>Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.</td></tr><tr><th>Mechanism of action</th><td>The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5&#8211;10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.</td></tr><tr><th>Absorption</th><td>28-100%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>8-12%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and &#945;-fluoro-&#223;-alanine) which are inactive. </p></td></tr><tr><th>Route of elimination</th><td>Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.
The remaining percentage of the administered dose is metabolized, primarily in the liver.</td></tr><tr><th>Half life</th><td>10-20 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=230mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Capecitabine Action Pathway</td><td>Drug action</td></tr><tr><td>Fluorouracil Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00470?highlight%5Bcompounds%5D%5B%5D=DB00544&amp;highlight%5Bproteins%5D%5B%5D=DB00544">SMP00470</a></td></tr><tr><td>Capecitabine Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00607?highlight%5Bcompounds%5D%5B%5D=DB00544&amp;highlight%5Bproteins%5D%5B%5D=DB00544">SMP00607</a></td></tr><tr><td>Fluorouracil Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00608?highlight%5Bcompounds%5D%5B%5D=DB00544&amp;highlight%5Bproteins%5D%5B%5D=DB00544">SMP00608</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Thymidylate synthase<br>Gene symbol: TYMS<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P04818" target="_blank">P04818 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs34743033" target="_blank">rs34743033 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>TSER*2</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Neutropenia, diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16818689" target="_blank" title="Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R: Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res. 2006 Jul 1;12(13):3928-34.">16818689 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Uridine 5'-monophosphate synthase<br>Gene symbol: UMPS<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P11172" target="_blank">P11172 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801019" target="_blank">rs1801019 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Neutropenia, diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16818689" target="_blank" title="Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R: Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res. 2006 Jul 1;12(13):3928-34.">16818689 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Dihydropyrimidine dehydrogenase [NADP(+)]<br>Gene symbol: DPYD<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q12882" target="_blank">Q12882 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801265" target="_blank">rs1801265 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Nausea, vomiting, reduced white cell count</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17848752" target="_blank" title="Zhang H, Li YM, Zhang H, Jin X: DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol. 2007;24(2):251-8.">17848752 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Dihydropyrimidine dehydrogenase [NADP(+)]<br>Gene symbol: DPYD<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q12882" target="_blank">Q12882 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801159" target="_blank">rs1801159 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G allele</td><td>Nausea, vomiting, reduced white cell count</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17848752" target="_blank" title="Zhang H, Li YM, Zhang H, Jin X: DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol. 2007;24(2):251-8.">17848752 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Glutathione S-transferase P<br>Gene symbol: GSTP1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P09211" target="_blank">P09211 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1695" target="_blank">rs1695 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele</td><td>Hematological toxicity, gastrointestinal toxicity</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18540691" target="_blank" title="Agostini M, Pasetto LM, Pucciarelli S, Terrazzino S, Ambrosi A, Bedin C, Galdi F, Friso ML, Mescoli C, Urso E, Leon A, Lise M, Nitti D: Glutathione S-Transferase P1 Ile105Val Polymorphism is Associated with Haematological Toxicity in Elderly Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. Drugs Aging. 2008;25(6):531-9.">18540691 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Dihydropyrimidine dehydrogenase [NADP(+)]<br>Gene symbol: DPYD<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q12882" target="_blank">Q12882 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3918290" target="_blank">rs3918290 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele</td><td>Leukopenia, diarrhea, mucositis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18299612" target="_blank" title="Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008 May 1;26(13):2131-8. Epub 2008 Feb 25.">18299612 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Dihydropyrimidine dehydrogenase [NADP(+)]<br>Gene symbol: DPYD<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q12882" target="_blank">Q12882 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs67376798" target="_blank">rs67376798 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T &gt; A</td><td>Patients are at a higher risk of toxicity</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/23603345" target="_blank" title='# Saif MW: Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):89-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23603345'>23603345 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9605</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9791</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7583</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7752</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8991</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9053</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7558</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9658</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9361</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9688</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9661</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9839</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8941
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9288
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.922
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2529 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9685
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9325
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Valeant pharmaceuticals international</li>
<li>Allergan herbert skin care div allergan inc</li>
<li>Spear pharmaceuticals inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Pharmacia and upjohn co</li>
<li>Teva parenteral medicines inc</li>
<li>Abic ltd</li>
<li>Abraxis pharmaceutical products</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Bioniche pharma usa llc</li>
<li>Ebewe pharma ges mbh nfg kg</li>
<li>Marchar laboratories inc ltd</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Watson laboratories inc</li>
<li>Elorac inc</li>
<li>Taro pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.healthbeautysolutions.com">Amcol Health and Beauty Solutions</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li>APPD</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li>Bigmar Bioren Pharmaceuticals Sa</li>
<li><a href="http://www.contractpharma.com">Contract Pharm</a></li>
<li><a href="http://www.creativecosmetics.com">Creative Cosmetics Inc.</a></li>
<li>Dermik Labs</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.ebewe.at">Ebewe Pharma</a></li>
<li><a href="http://www.generamedix.com">Generamedix Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.intaspharma.com">Intas Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Oceanside Pharmaceuticals Incorporated</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.legacypharmaceuticals.com">Solco Healthcare US LLC</a></li>
<li><a href="http://www.spearpharma.com">Spear Dermatology Products Inc.</a></li>
<li><a href="http://www.synerxpharma.com">Synerx Pharma LLC</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Cream</td><td>Topical</td><td>0.5%, 1%, 2%, 5%</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>500 mg/10 mL; 500 mg/10 mL; 1 g/20 mL; 2.5 g/50 mL;  5 g/100 mL   </td></tr><tr><td>Solution</td><td>Topical</td><td>2%, 5%</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Risk of 5-FU toxicity when associated with metronidazole</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Co-administration of Temsirolimus and Fluorouracil may result in serious adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluorouracil is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed.	</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Vitamin B1 needs increased with long term use.</li></ul></td></tr></tbody></table>